TTUHSC School of Pharmacy
HomeSOPFaculty & Staff Directory

Faculty & Staff Details

Profile for Ron Hall II, PharmD, MSCS

Ronald Hall

Ron Hall II, PharmD, MSCS

  • Associate Professor
Office Phone: 214-654-9404 ext 231
Mail Address: 5920 Forest Park Rd Ste 400
Dallas TX 75235-6418


Dr. Hall serves as the program director for the Dose Optimization and Outcomes Research (DOOR) progam. The DOOR program focuses on providing evidence to optimize the dosing and outcomes of medications for obese patients. Dr. Hall was selected as a National Institutes of Health Clinical Research Scholar in 2006. He was also the recipient of the 2008 Young Alumni Award from the St. Louis College of Pharmacy.

Research Interests

obesity, pharmacokinetics, antimicrobial, cancer, outcomes research

Selected Publications:

  • Hall RG, Blaszczyk AT, Thompson KA, Brouse SD, Giuliano CA, Frei CR, Forcade NA, Mortensen EM, Bell TE, Bedimo RJ, Alvarez CA. Impact of empiric weight-based vancomycin dosing on nephrotoxicity and mortality in geriatric patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Pharm Ther. 2014;:5.
  • Payne KD, Hall RG. Dosing of antibacterial agents in obese adults: Does one size fit all?. Expert Rev Anti Infect Ther. 2014;12(7):829-54.
  • Alvarez CA, Giuliano CA, Haase KK, Thompson KA, Frei CR, Forcade NA, Brouse SD, Mortensen EM, Bell T, Bedimo RJ, Toups NM, G. Empiric Weight-Based Vancomycin in Intensive Care Unit Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia.. The American journal of the medical sciences. 2014.
  • Pusch T, Pasipanodya JG, G, Gumbo T. Therapy duration and long-term outcomes in extra-pulmonary tuberculosis.. BMC infectious diseases. 2014;14:115.
  • Hall RG, Swancutt MA, Meek CC, Leff RD, Gumbo T. Weight drives caspofungin variability in overweight and obese people: fractal power signatures beyond 2/3 or 3/4. Antimicrob Agents Chemother. 2013;57(5):2259-64.